<p>不幸的是，對於一些股東來説，<strong>C4 Therapeutics, Inc.</strong>（納斯達克代碼：CCCC）的股價在過去三十天內下跌了 40%，延續了近期的痛苦。對於任何長期股東來説，上個月的表現結束了一個令人遺忘的年份，鎖定了 82% 的股價下跌。</p>
<p>在經歷如此大幅的價格下跌後，C4 Therapeutics 目前可能看起來是一個強有力的買入機會，其市銷率（&#34;P/S&#34;）為 2.5 倍，考慮到美國生物技術行業幾乎一半的公司市銷率超過 8.8 倍，甚至市銷率超過 51 倍的情況也並不罕見。不過，僅僅將市銷率視為表面值並不明智，因為可能有解釋説明其如此有限的原因。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對 C4 Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761"/></p>
<p>納斯達克 GS:CCCC 市銷率與行業比較 2025 年 4 月 18 日</p>
<h3>C4 Therapeutics 最近的表現如何？</h3>
<p>C4 Therapeutics 的表現可能更好，因為它的收入增長低於大多數其他公司。市銷率可能較低是因為投資者認為這種乏善可陳的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望收入不會變得更糟，並且能夠在它不受歡迎時買入一些股票。</p>
<p>如果你想了解分析師對未來的預測，你應該查看我們關於 C4 Therapeutics 的 <strong>免費</strong> 報告。</p>
<h2>C4 Therapeutics 是否有收入增長的預測？</h2>
<p>你真正會感到舒適的唯一情況是，當 C4 Therapeutics 的市銷率如此低迷時，公司的增長明顯落後於行業。</p>
<p>如果我們回顧過去一年的收入增長，公司實現了 71% 的可喜增長。然而，這還不夠，因為最近三年期間公司總收入經歷了 22% 的大幅下滑。因此，可以公平地説，最近的收入增長對公司來説是令人失望的。</p>
<p>展望未來，根據跟蹤該公司的八位分析師的預測，收入預計將下滑，未來三年每年收縮 20%。當行業其他公司預計每年增長 173% 時，這並不好。</p>
<p>考慮到這一點，我們發現 C4 Therapeutics 的市銷率與其行業同行非常接近。然而，收入的萎縮不太可能在長期內導致穩定的市銷率。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
<h2>C4 Therapeutics 市銷率的底線</h2>
<p>C4 Therapeutics 的股價幾乎跌入深淵，其市銷率也隨之大幅下滑。通常情況下，我們會警告在做出投資決策時不要過於關注市銷率，儘管它可以揭示市場其他參與者對公司的看法。</p>
<p>正如我們所懷疑的，我們對 C4 Therapeutics 分析師預測的審查顯示，收入萎縮的前景正在導致其市銷率低迷。目前，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。在這種情況下，很難看到股價在不久的將來強勁上漲。</p>
<p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>C4 Therapeutics 的 4 個警告信號</strong>（其中 1 個令人擔憂！）你應該瞭解。</p>
<p><strong>如果你對過去盈利增長穩健的公司感興趣</strong>，你可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>
<p>如果你想交易 C4 Therapeutics，請在專業人士信任的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的水平。</p>
<p>贊助內容</p>

CCCC

<p>C4 Therapeutics, Inc.（納斯達克代碼：CCCC）的股價在過去一個月內暴跌了 40%，年內累計下降了 82%。儘管其市銷率（P/S）僅為 2.5 倍，顯示出潛在的買入機會，但公司的收入增長令人失望，預測未來三年年均將下降 20%。分析師指出，低市銷率反映了市場對未來收入表現的懷疑，因此短期內股價強勁反彈的可能性不大。此外，關於公司財務健康狀況，還有四個警示信號需要考慮</p>

<p>Unfortunately for some shareholders, the <strong>C4 Therapeutics, Inc.</strong> (NASDAQ:CCCC) share price has dived 40% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends a year to forget by locking in a 82% share price decline.</p>
<div class="lb-trans"><p>不幸的是，對於一些股東來説，<strong>C4 Therapeutics, Inc.</strong>（納斯達克代碼：CCCC）的股價在過去三十天內下跌了 40%，延續了近期的痛苦。對於任何長期股東來説，上個月的表現結束了一個令人遺忘的年份，鎖定了 82% 的股價下跌。</p>
</div><p>After such a large drop in price, C4 Therapeutics may look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 2.5x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.8x and even P/S higher than 51x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.</p>
<div class="lb-trans"><p>在經歷如此大幅的價格下跌後，C4 Therapeutics 目前可能看起來是一個強有力的買入機會，其市銷率（&#34;P/S&#34;）為 2.5 倍，考慮到美國生物技術行業幾乎一半的公司市銷率超過 8.8 倍，甚至市銷率超過 51 倍的情況也並不罕見。不過，僅僅將市銷率視為表面值並不明智，因為可能有解釋説明其如此有限的原因。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>See our latest analysis for C4 Therapeutics</p>
<div class="lb-trans"><p>查看我們對 C4 Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761" alt="" original-src="https://images.simplywall.st/asset/chart/321572356-ps-multiple-vs-industry-1-dark/1744974719761"/></p>
<p>NasdaqGS:CCCC Price to Sales Ratio vs Industry April 18th 2025</p>
<div class="lb-trans"><p>納斯達克 GS:CCCC 市銷率與行業比較 2025 年 4 月 18 日</p>
</div><h3>How Has C4 Therapeutics Performed Recently?</h3>
<div class="lb-trans"><h3>C4 Therapeutics 最近的表現如何？</h3>
</div><p>C4 Therapeutics could be doing better as it's been growing revenue less than most other companies lately. The P/S ratio is probably low because investors think this lacklustre revenue performance isn't going to get any better. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>C4 Therapeutics 的表現可能更好，因為它的收入增長低於大多數其他公司。市銷率可能較低是因為投資者認為這種乏善可陳的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望收入不會變得更糟，並且能夠在它不受歡迎時買入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on C4 Therapeutics.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，你應該查看我們關於 C4 Therapeutics 的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For C4 Therapeutics?</h2>
<div class="lb-trans"><h2>C4 Therapeutics 是否有收入增長的預測？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as C4 Therapeutics' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>你真正會感到舒適的唯一情況是，當 C4 Therapeutics 的市銷率如此低迷時，公司的增長明顯落後於行業。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 71%. However, this wasn't enough as the latest three year period has seen the company endure a nasty 22% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>如果我們回顧過去一年的收入增長，公司實現了 71% 的可喜增長。然而，這還不夠，因為最近三年期間公司總收入經歷了 22% 的大幅下滑。因此，可以公平地説，最近的收入增長對公司來説是令人失望的。</p>
</div><p>Looking ahead now, revenue is anticipated to slump, contracting by 20% per annum during the coming three years according to the eight analysts following the company. That's not great when the rest of the industry is expected to grow by 173% each year.</p>
<div class="lb-trans"><p>展望未來，根據跟蹤該公司的八位分析師的預測，收入預計將下滑，未來三年每年收縮 20%。當行業其他公司預計每年增長 173% 時，這並不好。</p>
</div><p>With this in consideration, we find it intriguing that C4 Therapeutics' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>考慮到這一點，我們發現 C4 Therapeutics 的市銷率與其行業同行非常接近。然而，收入的萎縮不太可能在長期內導致穩定的市銷率。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
</div><h2>The Bottom Line On C4 Therapeutics' P/S</h2>
<div class="lb-trans"><h2>C4 Therapeutics 市銷率的底線</h2>
</div><p>Having almost fallen off a cliff, C4 Therapeutics' share price has pulled its P/S way down as well. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>C4 Therapeutics 的股價幾乎跌入深淵，其市銷率也隨之大幅下滑。通常情況下，我們會警告在做出投資決策時不要過於關注市銷率，儘管它可以揭示市場其他參與者對公司的看法。</p>
</div><p>As we suspected, our examination of C4 Therapeutics' analyst forecasts revealed that its outlook for shrinking revenue is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>正如我們所懷疑的，我們對 C4 Therapeutics 分析師預測的審查顯示，收入萎縮的前景正在導致其市銷率低迷。目前，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。在這種情況下，很難看到股價在不久的將來強勁上漲。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>4 warning signs for C4 Therapeutics</strong> (of which 1 is concerning!) you should know about.</p>
<div class="lb-trans"><p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>C4 Therapeutics 的 4 個警告信號</strong>（其中 1 個令人擔憂！）你應該瞭解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果你對過去盈利增長穩健的公司感興趣</strong>，你可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>
</div><p>If you're looking to trade C4 Therapeutics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你想交易 C4 Therapeutics，請在專業人士信任的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的水平。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

投資者對 C4 Therapeutics, Inc.（NASDAQ:CCCC）前景不看好，導致股價下跌 40%